We are live on ! Find out more

Lucid Diagnostics

LUCD

Market cap $74M

0.3873 USD

-0.0028

0.72%

At close Updated Nov 6, 11:46 AM EST

1 day

-0.72%

5 days

-4.37%

1 month

-35.45%

3 months

-59.36%

6 months

-64.14%

Year to date

-65.42%

1 year

-63.8%

5 years

-96.18%

10 years

-96.71%

About: Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Employees: 82

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 78.6%

Negative 7.1%

Zacks Investment Research

Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue Estimates

Mettler-Toledo (MTD) came out with quarterly earnings of $12.57 per share, beating the Zacks Consensus Estimate of $12.11 per share. This compares to earnings of $11.15 per share a year ago.

Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue Estimates

Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named a GenomeWeb 2026 Best Places to Work honoree, marking its second consecutive year in the annual program recognizing top workplaces across the life sciences research, diagnostics and precision medicine sectors. "Our team's shared passion and relentless dedication to preventing esophageal cancer are the foundation of our success," said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics.

Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 11, 2026 in New York City. Lishan Aklog, M.D.

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study

Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck ® cell collection in under two minutes NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of findings from the largest real-world clinical experience of nonendoscopic esophageal precancer testing to date, using the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. The manuscript, " Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: Real-World Experience in 11,991 Patients ," published in the journal Diagnostics , reported that EsoCheck cell collection was rapid, well tolerated, and consistent across operators, including newly trained personnel.

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study

PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026

Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, November 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D.

PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026

Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026

Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D.

Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The Company also closed a $15.0 million private placement on October 21, 2026, for shares of its newly designated Series C Convertible Preferred Stock (the "Series C Preferred Stock") to existing long-term shareholders.

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response from the CDC/NCHS ICD-10 Coordination and Maintenance Committee NEW YORK, Sept. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced advances in multiple payment, billing, and coding pathways for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, following three public meetings held last week.

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

Lucid Diagnostics NASDAQ: LUCD is positioning its EsoGuard test as a non-invasive tool to identify Barrett's Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a key Medicare coverage decision and expands relationships with commercial payers, the Department of Veterans Affairs and health systems.

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ® Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the second quarter ended June 30, 2026. Conference Call and Webcast The webcast will take place on Friday, August 14, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™